[1]
Baughman, R.P. et al. 2021. Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial.
Sarcoidosis, Vasculitis and Diffuse Lung Diseases. 38, 3 (Sep. 2021), e2021035. DOI:
https://doi.org/10.36141/svdld.v38i3.11684.